Medical Cannabis and London Families: What to Ask About Follow-Up Frequency

For many London families exploring medical cannabis as a possible treatment option, understanding how ongoing follow-ups and monitoring arrangements are handled is critical. The decision to continue or discontinue any treatment should be grounded in clear clinical evidence, safety monitoring, and alignment with established guidelines. This is especially important when the treatment is being considered for complex conditions like autism spectrum disorder (ASD) or its frequent co-occurring conditions.

Understanding the Symptom Being Treated: Autism vs Co-Occurring Conditions

Before diving into the specifics of follow-up frequency, it’s essential to clarify what symptom or condition medical cannabis aims to address. Autism itself is a neurodevelopmental condition characterized by differences in social communication and behavior patterns. However, many individuals with autism have co-occurring conditions such as:

• Epilepsy
• Anxiety disorders
• Attention deficit hyperactivity disorder (ADHD)
• Sleep disturbances
• Challenging behaviors

Current NICE (National Institute for Health and Care Excellence) guidance does not recommend medical cannabis for autism features alone. Instead, any consideration of such treatments usually relates to specific co-occurring symptoms, particularly drug-resistant epilepsy.

As families ask about ongoing follow-ups, one of the first checkpoints should be: “Are we targeting autism symptoms directly, or a co-occurring condition that might have some regulatory approval for medical cannabis use?”

NICE Guidance and What It Does—and Does Not—Recommend

The NICE guidance library offers comprehensive, evidence-based recommendations for clinical practice across the NHS, including on medical cannabis. However, the guidance is strict in specifying which indications have evidence robust enough to recommend cannabis-based products.

According to NICE and the General Medical Council (GMC) professional standards:

• Medical cannabis is only recommended for rare, treatment-resistant forms of epilepsy, specifically Dravet syndrome and Lennox-Gastaut syndrome. These are severe epilepsy syndromes marked by multiple seizure types and poor response to conventional therapies.
• There is currently insufficient evidence to advocate for medical cannabis in autism, anxiety, ADHD, or sleep disorders.
• Outcomes should be measurable and carefully documented as part of follow-up, avoiding vague reports like “seems calmer” without objective data.

Families have every right to ask prescribing clinicians detailed questions about how follow-up appointments will be structured, what monitoring tools will be used, and how continuation decisions will be made.

Narrow Epilepsy Indications: Dravet and Lennox-Gastaut

Because NICE recognizes medical cannabis for specific epilepsies, many specialist clinics use this as a framework for prescribing and monitoring. The follow-up frequency and monitoring in these children typically involve:

1. Baseline clinical assessments and seizure frequency logs
2. Regular follow-ups to observe for efficacy and side effects
3. Possible blood tests for drug levels and safety
4. Multidisciplinary input including neurology and pharmacy

For these indications, families should be able to expect more structured follow-up schedules, such as monthly appointments initially, then spacing out if stable. This contrasts with the informal or anecdotal monitoring sometimes reported in unregulated private clinics for other conditions.

Evidence Limits and Placebo Effects: What Families Should Know

While some families report subjective improvements in behavior or anxiety after starting medical cannabis, it is important to bear in mind the limits of current CBD for autism sleep evidence:

• Most studies outside epilepsy are small, observational, or anecdotal, making it difficult to draw reliable conclusions.
• Placebo effects and natural symptom fluctuations can explain many perceived benefits.
• Unmeasured outcomes without patient-reported scales or objective measurement limit meaningful evaluation.

Families should raise the following questions during consultations to ensure any treatment trial is rigorous:

• How will symptom changes be measured and recorded during follow-up?
• What will be the criteria to continue or discontinue the treatment?
• How often will safety and side effect monitoring occur?
• Is there a plan for withdrawal or dose adjustment if no benefit is observed?

Checklist for Families: What to Ask About Follow-Up Frequency and Monitoring

Topic Key Questions to Ask Why It Matters Target Condition Is this treatment for autism itself or a co-occurring condition?Is this condition recognized by NICE for medical cannabis? Ensures clear rationale and appropriate use Follow-Up Frequency How often will we have follow-ups initially?What factors determine if appointments get further apart? Sets expectations for ongoing care and monitoring Monitoring Methods What tools or scales will be used to measure symptom changes?Will there be objective assessments or just subjective reports? Facilitates evidence-based continuation decisions Safety Checks Will blood tests or other safety monitoring be done?What side effects should we watch for? Ensures treatment is safe over time Continuation Criteria What defines success or failure?When will the treatment be stopped if no benefit is observed? Prevents unnecessary prolonged exposure without benefit

The Role of GMC and Professional Standards in Follow-Up

The General Medical Council (GMC) sets out professional standards that all doctors must follow. This includes:

• Regularly reviewing the patient’s condition and the effectiveness of prescribed treatments
• Clearly documenting the rationale for ongoing prescriptions
• Discussing risks, benefits, and alternatives with patients and their families
• Ensuring ongoing consent and engagement with the monitoring process

Families have the right to expect this standard of care regardless of setting, and can refer to GMC guidance to hold providers accountable.

Summary and Take-Home Points for London Families

• Medical cannabis is not currently recommended by NICE for autism itself but only for narrow epilepsy indications like Dravet and Lennox-Gastaut syndromes.
• Clear and structured ongoing follow-ups and monitoring are essential components of safe prescribing.
• Families should insist on measurable symptom assessments, safety checks, and predefined criteria for continuation or stopping treatment.
• Beware of vague claims and treatments without follow-up plans; ask about how placebo effects are being accounted for.
• The GMC provides professional standards to guide clinicians in safe and effective prescribing and monitoring.

Here's what kills me: equipped with these points and questions, london families can navigate conversations with medical cannabis prescribers more confidently, ensuring that any treatment pursued is responsibly managed and supported by the best available evidence and clinical governance.